Joint FDA Panel Backs Safety of Drospirenone Contraceptives

Drug Industry Daily
A joint FDA advisory panel has concluded that the benefits of drospirenone birth control outweigh the increased risk of blood clots, saying data from various observational postmarket clinical trials are too conflicting and the risks, in any case, are rare among drospirenone users.

To View This Article:


Subscribe To Drug Industry Daily